Faes Farma SA

FAE

Equity

ISIN ES0134950F36 / Valor 2837976

BME Bolsas y Mercados Espanoles - Renta Variable (2025-04-04)

EUR 3.89-4.66%

Faes Farma SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Faes Farma SA is a pharmaceutical company based in Leioa, Spain, with additional offices and subsidiaries in various countries around the world. The company is primarily focused on the research, development, manufacturing, and marketing of prescription medicines, healthcare products, and animal nutrition products. Faes Farma SA is actively engaged in the pharmaceutical industry, producing a range of products to meet the needs of healthcare professionals and consumers globally.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the first quarter of 2023, Faes Farma SA reported a total income of 473 million euros, marking a 2.5% increase compared to the previous year. This growth was primarily driven by the strong performance of their top three pharmaceutical molecules, which collectively saw an 8% increase in revenue.

Profitability

Faes Farma SA achieved a net profit of 92 million euros in Q1 2023, setting a new record for the company. This represents a 2.5% increase from the previous year, highlighting the company's consistent growth in profitability over the past 11 years.

EBITDA and EBIT

The company's EBITDA for the first quarter of 2023 was 122 million euros, reflecting a 1.2% increase from the previous year. Similarly, the EBIT rose by 1.3% to reach 103 million euros, indicating stable operational efficiency despite the challenges in the market.

International Market Performance

International markets continued to be a significant growth driver for Faes Farma SA in Q1 2023, accounting for 56% of total revenues. The company saw substantial growth in Latin American and Middle Eastern markets, with an 8% increase in international pharmaceutical sales excluding licenses.

Investment and Outlook

Faes Farma SA invested 97 million euros in capital expenditures during the first quarter of 2023, primarily for the construction of a new production plant in Derio. The company remains optimistic about future growth, with plans to launch new products and expand into additional international markets.

Summarized from source with an LLMView Source

Key figures

23.1%1Y

4.29%3Y

13.5%5Y

Performance

16.8%1Y

17.5%3Y

23.7%5Y

Volatility